Related Experiment Video
Updated: Apr 16, 2026
07:43
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
20.2K
Pegvisomant Treatment in Acromegaly
Sebastian J C M M Neggers1, Ammar Muhammad, Aart Jan van der Lely
1Section of Endocrinology, Department of Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Neuroendocrinology
|March 21, 2015
Summary
Pegvisomant, a growth hormone receptor antagonist, is the most effective medical treatment for acromegaly, used alone or with somatostatin analogues. This review examines its efficacy and side effects in clinical studies.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Medical treatment for acromegaly has evolved significantly, with somatostatin analogues now central to therapy.
- Pegvisomant, a growth hormone receptor antagonist, represents a newer, highly effective option for acromegaly management.
Purpose of the Study:
- To review the clinical evidence on the efficacy of pegvisomant monotherapy and combination therapy for acromegaly.
- To provide an overview of the side effects associated with pegvisomant treatment.
Main Methods:
- Review of clinical studies and patient cohorts.
- Analysis of documented efficacy data for pegvisomant therapies.
- Compilation of reported side effects.
Main Results:
- Pegvisomant is the most effective medical treatment for acromegaly currently available.
- It demonstrates efficacy as both monotherapy and in combination with somatostatin analogues.
- The review provides a summary of associated adverse events.
Conclusions:
- Pegvisomant is a highly effective treatment for acromegaly, offering a valuable therapeutic option.
- Its use, despite cost, is supported by clinical evidence for both monotherapy and combination regimens.
- Understanding its efficacy and side effect profile is crucial for patient management.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
621
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
621
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
574
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
574
01:20Myasthenia Gravis: Overview and Treatment
3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
774
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
774
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K